Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter, randomized, double-blind, placebo-controlled dose-finding study of RO5313534 as adjunctive treatment to donepezil in mild to moderate Alzheimer's disease
2008-004012-13Phase 2Completed
- Sponsor
- Roche
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of facinicline in Alzheimer's disease (AD) (5 arms), sponsored by Roche. Primary endpoint: Change in ADAS-Cog score from baseline at week 24. Started Dec 2008; status: completed.
02
Drugs
facinicline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2008-004012-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004012-13.